Ultrastructure of Mouse Basal Cell Carcinoma Exhibiting Sebaceous Differentiation

Author(s):  
Victoria L. Wade ◽  
Winslow G. Sheldon ◽  
James W. Townsend ◽  
William Allaben

Sebaceous gland tumors and other tumors exhibiting sebaceous differentiation have been described in humans (1,2,3). Tumors of the sebaceous gland can be induced in rats and mice following topical application of carcinogens (4), but spontaneous mixed tumors of basal cell origin rarely occur in mice.

Author(s):  
Annette M. Andrews ◽  
Boon-Nam Blackwell ◽  
Terrell R. Hoage ◽  
Fred F. Kadiubar

Basal cell carcinoma with sebaceous gland differentiation has been described in mice and humans but spontaneous skin tumors of this type are uncommon in the rat.The tumor specimen was taken from a 26 month old male Wistar rat. Electron microscopy specimens were fixed by immersion in cacodylatebuffered 4% glutaraldehyde, post-fixed in 1% osmium tetroxide, dehydrated, cleared and embedded by standard procedures. Semi-thin (μm) sections were stained with ethanolic uranyl acetate followed by lead citrate, then examined on a Philips EM201 electron microscope.


2020 ◽  
Vol 2 (9) ◽  
pp. 01-06
Author(s):  
Samia Kamal

Background: Honeybee’s venom is potent anticancer drug without exhibiting any side effects. Skin Basal Cell Carcinoma (SBCC) is a common malignancy. It can cause significant local destructions depending on affected site. The diagnosis of SBCC can be suspected from clinical findings and confirmation of diagnosis histopathology. The present SBCC is recurrent and aggressive in the skin of head [upper right, in front of the right ear]; the patient was 65 years old in time of first intervention. Materials & Methods: Following the lesions primarily surgically excised, the malignant growths recurrent and visual recognition occurred after 1 year from first operation, then another (the second) surgical removal of SBCC from affected skin with removal of all skin layers near the affected site but another recurrence visually occurs after about 4 months, in the form of malignant growth in the skin of right ear. Dry honeybee’s venom 1 mg was dissolved in 1 ml dist. water as injectable solution. Moreover, ointment contains 2% bee venom was prepared to be used topically inside affected ear as injection is not possible. Results: Before this novel intervention, the desperate patient situation seems very dangerous; as the new growths appear as continuous spread near the removed skin, so that patient’s family decided to apply more noninvasive and non-surgical intervention. The only precaution was testing the patients to assure she is not hypersensitive to honeybees’ venom. The treatment performed by subcutaneous injection of 0.3 ml from prepared Honeybees venom (0.1 % conc.) in the skin of affected part of the ear. Subcutaneous infiltration was applied around the lesions of about 0.5 ml as well, topical application of the ointment inside inner part of affected ear. This process repeated daily with cleaning of the ear every time by suitable safe and sterile saline solutions. Management of healing process was enhanced by ascorbic acid solution as topical application on dead cancer cells and to help in exudates debris removal. The complete removal of malignant growths and recovery obtained after 1 month from first bee venom injections. No recurrence of SBCC seen for 3 yrs. Conclusions: Honeybees venom is highly effective and safe anticancer drug that can be used for all patients’ categories of all ages. Regarding the present case invasive surgical intervention was not the good choice from the beginnings, as recurrence and giving chance for spreading following the time lapse between every surgery.


2006 ◽  
Vol 126 (2) ◽  
pp. 265-271 ◽  
Author(s):  
Even Angell-Petersen ◽  
Roar Sørensen ◽  
Trond Warloe ◽  
Ana Maria Soler ◽  
Johan Moan ◽  
...  

1996 ◽  
Author(s):  
Sigrid Karrer ◽  
Christoph Abels ◽  
Rolf-Markus Szeimies ◽  
Wolfgang Baeumler ◽  
Ulrich Hohenleutner ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document